SecBot SecBot
6-K ·Filed Aug 24, 2026

MESO

MESOBLAST LTD
NEUTRAL
Impact 3/10
Horizondays Processed2mo ago SEC0001345099-26-000076
Notable filing: 6-K
Actionable Insight • Neutral

The filing is a routine notice of an upcoming earnings webcast. No actionable trading signal is present. Monitor the webcast on August 26-27 for the actual FY2026 financial results and any material updates on pipeline or commercial progress.

DirectionNeutral
Confidencehigh
Horizondays

Drugs in focus

MESO drug pipeline →

rexlemestrocel-L

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$16.64
T+0 close · Aug 24, 2026 · via day close
Latest settled
−4.33%
T+20 · $15.92 · next T+60 in 4h
Vs SPY
−5.64%
α at T+20
Latest observation
−18.73%
T+57 · FF3 residual α
  1. T+0 · Aug 24 $16.64entry
  2. T+1 · 3mo ago +3.31%α +2.99% · $17.19
  3. T+5 · 3mo ago +0.72%α +0.25% · $16.76
  4. T+20 · 8w ago −4.33%α −5.64% · $15.92
  5. T+59 · todayOpen
  6. T+60 · in 4h Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast filed a 6-K announcing a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The filing is a routine notice of an upcoming earnings event and contains no actual financial data or material corporate developments. The webcast is scheduled for August 26-27, 2026.

Key Facts

  • Mesoblast will host a webcast on August 26-27, 2026, to discuss FY2026 financial results and operational highlights.
  • The filing is a notice of an upcoming event and contains no financial figures or material business updates.
  • Ryoncil (remestemcel-L) is the first FDA-approved MSC therapy for SR-aGvHD in pediatric patients.

Financial Impact

No financial data provided in the filing.

Risk Factors

  • No financial data or guidance was provided in this filing, limiting its immediate informational value.
  • The filing does not disclose any material risks or changes to the company's outlook.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001345099-26-000076
Document: 0001345099-26-000076-index-headers.html0001345099-26-000076
Document: 0001345099-26-000076-index.html0001345099-26-000076
Document: 0001345099-26-000076.txt0001345099-26-000076

Track record

25 reports on MESO

Performance horizon

7 of 15 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 24, 2026